Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this study, we investigated the functional and clinical significance of the long non-coding RNA (lncRNA)
FAM181A-AS1
in human gliomas. TCGA, GTEx and CGGA database analyses showed that high
FAM181A-AS1
expression correlates with advanced tumor stage and poor survival of
glioma
patients.
FAM181A-AS1
expression is higher in
glioma
cell lines compared to normal human astrocytes (NHA). CCK-8, EdU, and colony formation assays show that
FAM181A-AS1
knockdown decreases proliferation and colony formation in
glioma
cells, whereas,
FAM181A-AS1
overexpression reverses these effects. Bioinformatics analysis showed that miR-129-5p is a potential target of
FAM181A-AS1.
MiR-129-5p expression negatively correlates with
FAM181A-AS1
expression in
glioma
patients. Dual luciferase reporter assays confirmed that miR-129-5p binds directly to
FAM181A-AS1
in
glioma
cells. RNA immunoprecipitation (RIP) assays using anti-Ago2 antibody pulled down
FAM181A-AS1
with miR-129-5p. Bioinformatics analysis identified
ZRANB2
as a potential miR-129-5p target gene. Dual luciferase reporter assays confirmed that miR-129-5p binds directly to the 3'-UTR of
ZRANB
2 mRNA. Furthermore, miR-129-5p overexpression or
ZRANB2
knockdown reduces proliferation and colony formation of
FAM181A-AS1
overexpressing
glioma
cells. These findings show that
FAM181A-AS1
promotes gliomagenesis by enhancing
ZRANB2
expression by sponging of miR-129-5p.
...
PMID:LncRNA FAM181A-AS1 promotes gliomagenesis by sponging miR-129-5p and upregulating ZRANB2. 3308 May 70
